This was not exactly the answer I was looking for, mfetish. You still haven't given me the explanation as to why the experts in the field were so wrong about their own sales projections
As I recall INSMED was working on numerous activities in the pipeline. The short stature growth hormone was only one of their future revenues. The pipeline for the burn victims could bring in revenues much higher if approved. Do you know the status on the burn victim revenues? and the status on the trials with MS?
News 
Market Data 
Discover 
